参考文献/References:
[1] 中华医学会骨科学分会关节外科学组,中国医师协会骨科医师分会骨关节炎学组,国家老年疾病临床医学研究中心(湘雅医院),等.中国骨关节炎诊疗指南(2021年版)[J].中华骨科杂志,2021,41(18):1291-1314.
[2] 冯媛媛,罗亚萍,师静,等.膝骨关节炎患者关节疼痛与软骨下骨髓水肿的相关性研究[J].现代生物医学进展,2018,18(6):1155-1158.
[3] 常亮,秦江辉,史冬泉,等.骨关节炎与软骨下骨研究进展[J].中华骨与关节外科杂志,2019,12(10):827-832.
[4] JAIPRAKASH A,PRASADAM I,FENG J Q,et al.Phenotypic characterization of osteoarthritic osteocytes from the sclerotic zones:a possible pathological role in subchondral bone sclerosis[J].Int J Biol Sci,2012,8(3):406-417.
[5] VILLATORO-VILLAR M,KWOH C K.Bisphosphonates,bone and joint pain[J].Curr Osteoporos Rep,2021,19(4):417-428.
[6] PANAGIOTAKOU A,YAVROPOULOU M,NASIRI-ANSARI N,et al.Extra-skeletal effects of bisphosphonates[J/OL].Metabolism,2020,110:154264[2022-10-10].https://pubmed.ncbi.nlm.nih.gov/32445641/.
[7] 杨威,鲁艳芹,韩金祥.双膦酸盐类药物及其应用综述[J].罕少疾病杂志,2021,28(6):105-110.
[8] ITZSTEIN C,COXON F P,ROGERS M J.The regulation of osteoclast function and bone resorption by small GTPases[J].Small GTPases,2011,2(3):117-130.
[9] HOLSTEIN S A.A patent review of bisphosphonates in treating bone disease[J].Expert Opin Ther Pat,2019,29(5):315-325.
[10] PARK J,PANDYA V R,EZEKIEL S J,et al.Phosphonate and bisphosphonate inhibitors of farnesyl pyrophosphate synthases:a structure-guided perspective[J/OL].Front Chem,2021,8:612728[2022-10-10].https://pubmed.ncbi.nlm.nih.gov/33490038/.
[11] MATHOV I,PLOTKIN L I,SGARLATA C L,et al.Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro[J].J Bone Miner Res,2001,16(11):2050-2056.
[12] BABA T T,MIYAZAKI T,OHARA-NEMOTO Y,et al.Suppressive effects of N-bisphosphonate in osteoblastic cells mitigated by non-N-bisphosphonate but not by sodium-dependent phosphate cotransporter inhibitor[J].Cell Biochem Funct,2019,37(6):400-407.
[13] PLOTKIN L I,BUVINIC S,BALANTA-MELO J.In vitro and in vivo studies using non-traditional bisphosphonates[J/OL].Bone,2020,134:115301[2022-10-10].https://pubmed.ncbi.nlm.nih.gov/32112989/.
[14] LOTZ E M,LOHMANN C H,BOYAN B D,et al.Bisphosphonates inhibit surface-mediated osteogenesis[J].J Biomed Mater Res A,2020,108(8):1774-1786.
[15] ROELOFS A J,THOMPSON K,EBETINO F H,et al.Bisphosphonates:molecular mechanisms of action and effects on bone cells,monocytes and macrophages[J].Curr Pharm Des,2010,16(27):2950-2960.
[16] WANG L,MI B,ZHANG Y,et al.Alendronate promotes the gene expression of extracellular matrix mediated by SP-1/SOX-9[J].Hum Exp Toxicol,2021,40(7):1173-1182.
[17] 韩芸,韩伟,卢琼.阿仑膦酸钠对膝骨关节炎大鼠软骨细胞的保护作用[J].中国临床药理学杂志,2020,36(20):3321-3323.
[18] ROSA R G,COLLAVINO K,LAKHANI A,et al.Clodronate exerts an anabolic effect on articular chondrocytes mediated through the purinergic receptor pathway[J].Osteoarthritis Cartilage,2014,22(9):1327-1336.
[19] JIN Z H,WANG S F,LIAO W.Zoledronic acid accelerates osteogenesis of bone marrow mesenchymal stem cells by attenuating oxidative stress via the SIRT3/SOD2 pathway and thus alleviates osteoporosis[J].Eur Rev Med Pharmacol Sci,2020,24(4):2095-2101.
[20] DELANOIS R E,SAX O C,CHEN Z,et al.Biologic therapies for the treatment of knee osteoarthritis:an updated systematic review[J].J Arthroplasty,2022,37(12):2480-2506.
[21] VALENTI M T,MOTTES M,BIOTTI A,et al.Clodronate as a therapeutic strategy against osteoarthritis[J].Int J Mol Sci,2017,18(12):2696.
[22] 杨爽,闫景龙.软骨细胞分化过程中SOX9的作用[J].中国组织工程研究,2022,26(14):2279-2284.
[23] TAKIGAWA Y,HATA K,MURAMATSU S,et al.The transcription factor Znf219 regulates chondrocyte differentiation by assembling a transcription factory with Sox9[J].J Cell Sci,2010,123(Pt 21):3780-3788.
[24] WOOD M J,MILLER R E,MALFAIT A M.The genesis of pain in osteoarthritis:inflammation as a mediator of osteoarthritis pain[J].Clin Geriatr Med,2022,38(2):221-238.
[25] WOODELL-MAY J E,SOMMERFELD S D.Role of inflammation and the immune system in the progression of osteoarthritis[J].J Orthop Res,2020,38(2):253-257.
[26] PAN F,TIAN J,CICUTTINI F,et al.Prospective association between inflammatory markers and knee cartilage volume loss and pain trajectory[J].Pain Ther,2022,11(1):107-119.
[27] WANG X Z,LI W X.Changes of serum inflammatory factors and miR-145 expression in patients with osteoarthritis before and after treatment and their clinical value[J].World J Clin Cases,2019,7(19):2963-2975.
[28] 王哲彦,王文雅,张柳,等.阿仑膦酸钠对IL-1β体外诱导培养的大鼠膝关节软骨细胞影响的实验研究[J].中国修复重建外科杂志,2011,25(1):50-55.
[29] PERIS P,MONEGAL A,GUAÑABENS N.Bisphosphonates in inflammatory rheumatic diseases[J/OL].Bone,2021,146:115887[2022-10-10].https://pubmed.ncbi.nlm.nih.gov/33592328/.
[30] BAROJA-MAZO A,PELEGRÍN P.Modulating P2X7 receptor signaling during rheumatoid arthritis:new therapeutic approaches for bisphosphonates[J/OL].J Osteoporos,2012,2012:408242[2022-10-10].https://pubmed.ncbi.nlm.nih.gov/22830074/.
[31] ZHANG H,CAI D,BAI X.Macrophages regulate the progression of osteoarthritis[J].Osteoarthritis Cartilage,2020,28(5):555-561.
[32] XIE J,HUANG Z,YU X,et al.Clinical implications of macrophage dysfunction in the development of osteoarthritis of the knee[J].Cytokine Growth Factor Rev,2019,46:36-44.
[33] PATNTIRAPONG S,POOLGESORN M.Alteration of macrophage viability,differentiation,and function by bisphosphonates[J].Oral dis,2018,24(7):1294-1302.
[34] PATNTIRAPONG S,PHUPUNPORN P,VANICHTANTIPHONG D,et al.Inhibition of macrophage viability by bound and free bisphosphonates[J].Acta Histochem,2019,121(4):400-406.
[35] MAKKONEN N,SALMINEN A,ROGERS M J,et al.Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite[J].Eur J Pharm Sci,1999,8(2):109-118.
[36] VILLATORO-VILLAR M,KWOH C K.Bisphosphonates,bone and joint pain[J].Curr Osteoporos Rep,2021,19(4):417-428.
[37] TAYLOR S S,NOOR N,URITS I,et al.Complex regional pain syndrome:a comprehensive review[J].Pain Ther,2021,10(2):875-892.
[38] FREDIANI B,GIUSTI A,BIANCHI G,et al.Clodronate in the management of different musculoskeletal conditions[J].Minerva Med,2018,109(4):300-325.
[39] FREDIANI B,TOSCANO C,FALSETTI P,et al.Intramuscular clodronate in long-term treatment of symptomatic knee osteoarthritis:a randomized controlled study[J].Drugs R D,2020,20(1):39-45.
[40] TZSCHENTKE T M.Pharmacology of bisphosphonates in pain[J].Br J Pharmacol,2021,178(9):1973-1994.
[41] HAYAMI T,PICKARSKI M,WESOLOWSKI G A,et al.The role of subchondral bone remodeling in osteoarthritis:reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model[J].Arthritis Rheum,2004,50(4):1193-1206.
[42] STRASSLE B W,MARK L,LEVENTHAL L,et al.Inhibition of osteoclasts prevents cartilage loss and pain in a rat model of degenerative joint disease[J].Osteoarthritis Cartilage,2010,18(10):1319-1328.
[43] 陈建超.抗骨质疏松联合用药对骨质疏松症伴膝骨关节炎患者骨量分布的影响[D].唐山:华北理工大学,2021.
[44] NEOGI T,LI S,PELOQUIN C,et al.Effect of bisphosphonates on knee replacement surgery[J].Ann Rheum Dis,2018,77(1):92-97.
[45] VERTESICH K,SOSA B R,NIU Y,et al.Alendronate enhances osseointegration in a murine implant model[J].J Orthop Res,2021,39(4):719-726.
[46] WANG P,SHANG G Q,XIANG S,et al.Zoledronic acid and teriparatide have a complementary therapeutic effect on aseptic loosening in a rabbit model[J].BMC Musculoskelet Disord,2021,22(1):580.
[47] RO D H,JIN H,PARK J Y,et al.The use of bisphosphonates after joint arthroplasty is associated with lower implant revision rate[J].Knee Surg Sports Traumatol Arthrosc,2019,27(7):2082-2089.
[48] PRIETO-ALHAMBRA D,LALMOHAMED A,ABRAHAMSEN B,et al.Oral bisphosphonate use and total knee/hip implant survival:validation of results in an external population-based cohort[J].Arthritis Rheumatol,2014,66(11):3233-3240.
[49] NAMBA R S,INACIO M C S,CHEETHAM T C,et al.Lower total knee arthroplasty revision risk associated with bisphosphonate use,even in patients with normal bone density[J].J Arthroplasty,2016,31(2):537-541.
[50] SHI M,CHEN L,XIN Z,et al.Bisphosphonates for the pre-servation of periprosthetic bone mineral density after total joint arthroplasty:a meta-analysis of 25 randomized controlled trials[J].Osteoporos Int,2018,29(7):1525-1537.
[51] LEMS W F.Bisphosphonates:a therapeutic option for knee osteoarthritis?[J].Ann Rheum Dis,2018,77(9):1247-1248.
[52] YUAN X L,MENG H Y,WANG Y C,et al.Bone-cartilage interface crosstalk in osteoarthritis:potential pathways and future therapeutic strategies[J].Osteoarthritis Cartilage,2014,22(8):1077-1089.
[53] LASLETT L L,DORÉ D A,QUINN S J,et al.Zoledronic acid reduces knee pain and bone marrow lesions over 1 year:a randomised controlled trial[J].Ann Rheum Dis,2012,71(8):1322-1328.
[54] AGARWALA S,SHAROFF L,JAGANI N.Effect of zoledronic acid and alendronate on bone edema and pain in spontaneous osteonecrosis of the knee:a new paradigm in the medical management[J].Rev Bras Ortop(Sao Paulo),2020,55(5):543-550.
[55] HAYES K N,GIANNAKEAS V,WONG A K O.Bisphosphonate use is protective of radiographic knee osteoarthritis progression among those with low disease severity and being non-overweight:data from the osteoarthritis initiative[J].J Bone Miner Res,2020,35(12):2318-2326.
(收稿日期:2022-10-11 本文编辑:郭毅曼)